Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$128.36

1.74 (1.37%)

20:23
11/06/18
11/06
20:23
11/06/18
20:23

BMO Capital optimistic about Sage Therapeutics upcoming data readouts

BMO Capital analyst Gary Nachman kept his Outperform rating and $203 price target on Sage Therapeutics after its Q3 results, saying the company's "much higher SG&A" spending is "supporting preparations for an expected launch of Zulresso" for postpartum depression in March of 2019. The analyst anticipates approval for Zulresso by the December PDUFA following a "very favorable AdComm last week". Nachman is also positive on Sage Therapeutics' development of trials for SAGE-217 in major depressive disorders, which he claims may be "an even bigger opportunity if successful".

  • 06

    Nov

  • 06

    Nov

  • 27

    Nov

  • 19

    Dec

SAGE Sage Therapeutics
$128.36

1.74 (1.37%)

10/31/18
BMOC
10/31/18
NO CHANGE
Target $203
BMOC
Outperform
BMO sees approval for Sage after Zulresso briefing docs
The FDA this morning released briefing documents for Friday's panel meeting to discuss Sage Therapeutics' Zulresso to treat postpartum depression. It appears the FDA is satisfied with the drug's efficacy and overall tolerability and recognizes a significant unmet need for postpartum depression, BMO Capital analyst Gary Nachman tells investors in a research note. He believes Zulresso will likely be approved on the December 19 FDA action date. Nachman adds, however, that there are some questions on the recommended dosing, since initially the lower dose appears more effective but the doses start to separate during titration when going out beyond 24 hours. He has an Outperform rating on Sage Therapeutics with a $203 price target. The stock in early trading is up 1% to $122.47.
10/31/18
10/31/18
NO CHANGE
Target $206

Overweight
Sage briefing docs 'clearly supportive of approval,' says Piper Jaffray
In a midday research note partially titled "Nothing Too Spooky in Brex Briefing Docs," Piper Jaffray analyst Danielle Brill says this morning's FDA's briefing documents for Sage Therapeutics' brexanolone were overall supportive of approval for postpartum depression. The agency appears comfortable with brexanolone's efficacy, and focused on recommended dosing as a key topic of discussion, Brill writes in a note to investors. The major safety concern, loss of consciousness during infusion which occurred in 4% of women treated, does not appear to be barring of approval, says the analyst. However, Brill adds that while she views the tone of the docs as "clearly supportive of approval," prohibiting administration "at-home" has "obvious negative implications for commercial potential." She has an Overweight rating on Sage Therapeutics with a $206 price target. The stock in midday trading is up 6%, or $7.77, to $129.00.
11/01/18
ADAM
11/01/18
NO CHANGE
Target $220
ADAM
Buy
Sage Therapeutics FDA briefing documents read 'ok,' says Canaccord
Canaccord analyst Sumant Kulkarni noted the FDA posted its briefing documents related to Sage Therapeutics' brexanolone ahead of the advisory committee meeting on the product scheduled for November 2. The analyst said they appear "ok" and said the drug could be the first approved for the treatment of post-partum depression. The analyst said with the stock down roughly 10% since the FDA confirmed the date of the AdCom meeting, he is telling investors to buy the shares. Kulkarni reiterated his Buy rating and $220 price target on Sage Therapeutics shares.
11/06/18
11/06/18
NO CHANGE

Sage Therapeutics pricing for Zulresso at a premium to Piper Jaffray estimate
Piper Jaffray analyst Danielle Brill, who maintained an Overweight rating and $206 price target on Sage Therapeutics shares, noted that the announced plans to price Zulresso at $25,000-$35,000 per course -- should it be approved on its December 19 PDUFA date -- which is at a premium to Piper's estimated net pricing of $15,000. Brill also noted that the drug's sales force has been hired, which includes ~130 reps, and ~50 patient support/access personnel, and she is awaiting final commercial details following PDUFA announcement.

TODAY'S FREE FLY STORIES

08:35
11/19/18
11/19
08:35
11/19/18
08:35
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

FRME

First Merchants

$41.23

0.06 (0.15%)

08:33
11/19/18
11/19
08:33
11/19/18
08:33
Upgrade
First Merchants rating change  »

Sandler ONeill upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVH

PVH Corp.

$115.51

-1.84 (-1.57%)

08:33
11/19/18
11/19
08:33
11/19/18
08:33
Recommendations
PVH Corp. analyst commentary  »

PVH Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

CLX

Clorox

$162.02

1.51 (0.94%)

08:31
11/19/18
11/19
08:31
11/19/18
08:31
Conference/Events
Clorox management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

HP

Helmerich & Payne

$62.59

2.54 (4.23%)

08:31
11/19/18
11/19
08:31
11/19/18
08:31
Upgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INGR

Ingredion

$101.29

1.56 (1.56%)

08:30
11/19/18
11/19
08:30
11/19/18
08:30
Recommendations
Ingredion analyst commentary  »

Ingredion price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INXN

Interxion

$64.10

0.62 (0.98%)

08:30
11/19/18
11/19
08:30
11/19/18
08:30
Conference/Events
Interxion management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

FCSC

Fibrocell Science

$2.08

0.015 (0.73%)

, LPNT

LifePoint

$65.00

(0.00%)

08:30
11/19/18
11/19
08:30
11/19/18
08:30
Options
Five option delistings on November 19th »

Option delistings…

FCSC

Fibrocell Science

$2.08

0.015 (0.73%)

LPNT

LifePoint

$65.00

(0.00%)

NYRT

New York REIT

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHLD

National Holdings Corp

$2.96

(0.00%)

08:30
11/19/18
11/19
08:30
11/19/18
08:30
Hot Stocks
Breaking Hot Stocks news story on National Holdings Corp »

National Holdings Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENDP

Endo

$12.70

-0.035 (-0.27%)

08:29
11/19/18
11/19
08:29
11/19/18
08:29
Conference/Events
Endo management to meet with Cantor Fitzgerald »

Endo holds a Phase 3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 27

    Nov

SIX

Six Flags

$59.79

1 (1.70%)

08:27
11/19/18
11/19
08:27
11/19/18
08:27
Recommendations
Six Flags analyst commentary  »

Six Flags checks show Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACBI

Atlantic Capital

$17.32

0.04 (0.23%)

08:27
11/19/18
11/19
08:27
11/19/18
08:27
Upgrade
Atlantic Capital rating change  »

Atlantic Capital upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NVEE

NV5 Global

$73.44

-0.23 (-0.31%)

08:27
11/19/18
11/19
08:27
11/19/18
08:27
Hot Stocks
NV5 Global awarded $17M location, survey services contract from NCDOT »

NV5 Global announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNA

Arena Pharmaceuticals

$41.67

2.13 (5.39%)

08:26
11/19/18
11/19
08:26
11/19/18
08:26
Recommendations
Arena Pharmaceuticals analyst commentary  »

Arena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MATW

Matthews

$43.21

2.91 (7.22%)

08:25
11/19/18
11/19
08:25
11/19/18
08:25
Recommendations
Matthews analyst commentary  »

Matthews price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

08:25
11/19/18
11/19
08:25
11/19/18
08:25
Conference/Events
HSBC to hold a conference »

China Healthcare…

QURE

uniQure

$31.89

0.89 (2.87%)

08:25
11/19/18
11/19
08:25
11/19/18
08:25
Conference/Events
uniQure to host research and development day »

Research &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CFX

Colfax

$28.00

0.31 (1.12%)

08:25
11/19/18
11/19
08:25
11/19/18
08:25
Conference/Events
Colfax to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

UMRX

Unum Therapeutics

$8.07

0.1 (1.25%)

08:25
11/19/18
11/19
08:25
11/19/18
08:25
Conference/Events
Unum Therapeutics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 01

    Dec

ADIL

Adial Pharmaceuticals

$1.28

-0.05 (-3.76%)

08:24
11/19/18
11/19
08:24
11/19/18
08:24
Hot Stocks
Adial Pharmaceuticals engages Crown CRO to begin Phase 3 trial for AD04 »

Adial Pharmaceuticals and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:23
11/19/18
11/19
08:23
11/19/18
08:23
Conference/Events
Daiwa to hold a conference »

Asia Communication Days…

VICI

VICI Properties

$21.29

0.16 (0.76%)

08:22
11/19/18
11/19
08:22
11/19/18
08:22
Initiation
VICI Properties initiated  »

VICI Properties initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:20
11/19/18
11/19
08:20
11/19/18
08:20
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
11/19/18
11/19
08:20
11/19/18
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
11/19/18
11/19
08:20
11/19/18
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.